– Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation – Functional constipation in children is defined as a ...

– Data demonstrates that linaclotide reduces the need for rescue medications in this patient population – – Additional presentations further characterize the efficacy and safety profiles of ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

Please provide your email address to receive an email when new articles are posted on . Once-daily linaclotide improved weekly spontaneous bowel movements from 1.16 to 3.41 during the 12-week ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

Abdominal massage is emerging as a promising non‐invasive intervention for managing constipation across diverse patient populations. This therapy involves the application of rhythmic pressure and ...

A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

The US Food and Drug Administration (FDA) has expanded the indication for linaclotide (Linzess) to children as young as age 6 years with functional constipation, making it the first approved treatment ...

There are no known causes and usually multiple factors leading to the common condition that makes stools hard and difficult to pass, according to the FDA. Linzess was approved in 2012 for adult ...

At any given time, as many as four million Americans are suffering through bouts of constipation, which has many causes but can also prove stubborn to relieve and hugely impact daily life. Functional ...